Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

47
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
47
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

46
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
46
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

72
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
72
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

MitoSAM-dependent lipoylation controls postnatal heart development via metabolic remodeling.

bioRxiv : the preprint server for biology·2026
Same author

Hyperglycaemia, inflammation and early cardiac remodelling in non-surgically revascularized STEMI: the role of microvascular obstruction and intramyocardial haemorrhage.

Indian journal of thoracic and cardiovascular surgery·2026
Same author

Impact of the risk-treatment paradox on in-hospital and long-term outcomes in patients with very high-risk non-ST-elevation acute coronary syndrome.

The Indian journal of medical research·2026
Same author

Assessing coronary microvascular dysfunction in refractory no-reflow: Insights from dynamic myocardial perfusion scintigraphy and cardiac MRI.

Microvascular research·2025
Same author

Inflammatory Indices in Patients with Myocardial Infarction Complicated by Cardiogenic Shock, and Their Interconnections with SCAI Stages and Patients' Survival: A Retrospective Study.

Journal of clinical medicine·2025
Same author

Non-ischemic phenotypes of low-risk chest pain patients based on exercise stress echocardiography: a pilot study.

Frontiers in cardiovascular medicine·2025

関連する実験動画

Updated: Sep 10, 2025

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice
07:28

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice

Published on: July 2, 2018

9.2K

SCAI分類におけるA段階の心臓性ショック:診断改善の限界と展望

Stanislav Dil1, Maria Kercheva1, Nina Belich1

  • 1From the Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

Cardiology in review
|August 25, 2025
PubMed
まとめ

心臓発作性ショック (CS) のリスクを早期に特定することが重要です. バイオマーカーとダイナミックモニタリングを統合することで 患者の治療成果を向上させ 費用を削減できます

キーワード:
SCAIの分類心筋梗塞に関連したショックリスク予測ステージ A ショック

さらに関連する動画

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K

関連する実験動画

Last Updated: Sep 10, 2025

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice
07:28

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice

Published on: July 2, 2018

9.2K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K

科学分野:

  • 心臓病科
  • 緊急 医療
  • 緊急 治療

背景:

  • 心臓発作性ショック (CS) は,高い死亡率を持つ緊急心臓病における重要な課題です.
  • ステージAのような現在の分類システムには 精度が欠けていて 患者リスクの階層化は異質です
  • "広範な心筋梗塞"の曖昧な基準と微小血管機能障害/炎症を無視することは,早期の介入を妨げます.

研究 の 目的:

  • 初期段階の心臓性ショックにおけるリスクの階層化の必要性を強調する.
  • ショック進行のリスクのある患者を特定することの重要性を強調する.
  • 新しいバイオマーカーとダイナミックモニタリングを診断アルゴリズムに統合することを提唱する.

主な方法:

  • 心臓発作ショックの分類と進行に関する既存の文献のレビュー
  • ステージACSの現在の診断基準の限界の分析
  • 微循環障害と炎症バイオマーカーの新興役割の探求

主要な成果:

  • ステージAの分類は,非常に異なるリスクプロファイルを持つ患者を含め,著しい異質性を示しています.
  • 特定のバイオマーカーの欠如は,ショックに進行する可能性のある患者の正確な識別を妨げます.
  • 微小血管機能障害と全身性炎症は,CSの進行における過小評価されている要因です.

結論:

  • 画像と炎症バイオマーカーを含む診断アルゴリズムの改善が必要である.
  • 患者の状態のダイナミックな再評価 (乳酸,血動力学, perfusion) は極めて重要です.
  • リスクの精密な分層化による多学科的アプローチは,CSの適時かつ適切な介入に不可欠です.